For this study, researchers have reported that Durvalumab is a monoclonal antibody that binds to programmed death-ligand 1 (PD-L1) expressed on some cancer cells, thus preventing recognition by programmed death 1 on T cells and encouraging T-cell–mediated tumor destruction.
Durvalumab received regulatory approval for treatment of unresectable stage III non–small-cell lung cancer (NSCLC) after chemoradiotherapy in 2018 after this regimen was demonstrated to significantly improve median progression-free and overall survival. Currently, durvalumab consolidation is considered a standard treatment for most patients with stage III NSCLC after chemoradiotherapy. Most reported adverse events during durvalumab consolidation have been mild, but approximately 30% of patients will experience serious adverse events, most commonly pneumonia, pneumonitis, and anemia.
Nevertheless, as more patients have been treated with durvalumab, reports of unexpected complications not previously described in clinical trials have begun to emerge. Recently, for instance, a case of fatal bronchomediastinal fistula during durvalumab consolidation has been published.